Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Melphalan and Cyclophosphamide with Stem Cell Rescue for Recurrent Medulloblastoma and Germ Cell Tumors
NCT00002594Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Sep 1994
- Primary completion
- Sep 2003
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of melphalan and cyclophosphamide in medulloblastoma and central nervous system germ cell tumor, sponsored by Children's Oncology Group. Primary endpoints: Progression-free survival at 2 years, Response Rate and 1 more. Started Sep 1994; status: completed.
02
Drugs
melphalancyclophosphamide
03
Conditions
medulloblastomacentral nervous system germ cell tumor
Beyond the preview
Go deeper on NCT00002594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002594.